Protein degrader startup Plexium secured an additional $60 million in funding to support ongoing development following strategic pipeline realignments and the loss of its Amgen collaboration. The company continues to advance oral CRBN molecular glue degrader candidates targeting IKZF2 and SMARCA2, with preclinical to early clinical progress. Despite recent workforce reductions, Plexium emphasizes maintaining robust drug discovery and platform capabilities and preparing for clinical studies to address cancer therapeutics.